Loading…
Design and synthesis of gambogic acid analogs as potent cytotoxic and anti-inflammatory agents
Two pyranoxanthones (16 and 20) showed the greatest activity against the KBvin multidrug resistant (MDR) cell line with IC50 values of 0.9 and 0.8μg/mL, respectively. An angular 3-methyl-3-prenyl pyranoxanthone (17) selectively inhibited elastase release with 200 times more potency than PMSF, the po...
Saved in:
Published in: | Bioorganic & medicinal chemistry letters 2012-06, Vol.22 (12), p.4018-4022 |
---|---|
Main Authors: | , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | Two pyranoxanthones (16 and 20) showed the greatest activity against the KBvin multidrug resistant (MDR) cell line with IC50 values of 0.9 and 0.8μg/mL, respectively. An angular 3-methyl-3-prenyl pyranoxanthone (17) selectively inhibited elastase release with 200 times more potency than PMSF, the positive control.
Prenyl- and pyrano-xanthones derived from 1,3,6-trihydroxy-9H-xanthen-9-one, a basic backbone of gambogic acid (GA), were synthesized and evaluated for in vitro cytotoxic effects against four human cancer cell lines (KB, KBvin, A549, and DU-145) and anti-inflammatory activity toward superoxide anion generation and elastase release by human neutrophils in response to fMLP/CB. Among them, prenylxanthones 7–13 were generally less active than pyranoxanthones 14–21 in both anticancer and anti-inflammatory assays. Furthermore, two angular 3,3-dimethypyranoxanthones (16 and 20) showed the greatest and selective activity against the KBvin multidrug resistant (MDR) cell line with IC50 values of 0.9 and 0.8μg/mL, respectively. An angular 3-methyl-3-prenylpyranoxanthone (17) selectively inhibited elastase release with 200 times more potency than phenylmethylsulfonyl fluoride (PMSF), the positive control. |
---|---|
ISSN: | 0960-894X 1464-3405 |
DOI: | 10.1016/j.bmcl.2012.04.084 |